White Matter Atrophy and Cognitive Dysfunctions in Neuromyelitis Optica

Frederic Blanc1,2,3,*, Vincent Noblet4, Barbara Jung1,3, François Rousseau4, Felix Renard2,4, Bertrand Barre1,2, Nadine Longato1,3, Nadjette Cremel1,3, Laure Di Bitonto1,3, Catherine Kleitz1,3, Nicolas Collongues1,2, Jack Foucher5, Stephane Kremer2,6, Jean-Paul Armspach2, Jerome de Seze1,2

1Neuropsychology Service, Department of Neurology, University Hospital of Strasbourg, Strasbourg, France, 2LINC (Cognitive Neurosciences and Imagery Laboratory), UMR 7237, University of Strasbourg and CNRS, Strasbourg, France, 3CMRR (Memory Resource and Research Centre), Department of Neurology, University Hospital of Strasbourg, Strasbourg, France, 4LSIIT (Image Science, Computer Science and Remote Sensing Laboratory), UMR 7005, University of Strasbourg and CNRS, Strasbourg, France, 5INSERM U666, University Hospital of Strasbourg, Strasbourg, France, 6Neuroradiology service, University Hospital of Strasbourg, Strasbourg, France

Abstract

Neuromyelitis optica (NMO) is an inflammatory disease of central nervous system characterized by optic neuritis and longitudinally extensive acute transverse myelitis. NMO patients have cognitive dysfunctions but other clinical symptoms of brain origin are rare. In the present study, we aimed to investigate cognitive functions and brain volume in NMO. The study population consisted of 28 patients with NMO and 28 healthy control subjects matched for age, sex and educational level. We applied a French translation of the Brief Repeatable Battery (BRB-N) to the NMO patients. Using SIENAx for global brain volume (Grey Matter; GM; White Matter, WM; and whole brain) and VBM for focal brain volume (GM and WM), NMO patients and controls were compared. Voxel-level correlations between diminished brain concentration and cognitive performance for each tests were performed. Focal and global brain volume of NMO patients with and without cognitive impairment were also compared. Fifteen NMO patients (54%) had cognitive impairment with memory, executive function, attention and speed of information processing deficits. Global and focal brain atrophy of WM but not Grey Matter (GM) was found in the NMO patients group. The focal WM atrophy included the optic chiasm, pons, cerebellum, the corpus callosum and parts of the frontal, temporal and parietal lobes, including superior longitudinal fascicle. Visual memory, verbal memory, speed of information processing, short-term memory and executive functions were correlated to focal WM volumes. The comparison of patients with, to patients without cognitive impairment showed a clear decrease of global and focal WM, including brainstem, corticospinal tracts, corpus callosum but also superior and inferior longitudinal fascicles. Cognitive impairment in NMO patients is correlated to the decreased of global and focal WM volume of the brain. Further studies are needed to better understand the precise origin of cognitive impairment in NMO patients, particularly in the WM.

Introduction

Neuromyelitis optica (NMO) is a central nervous system (CNS) inflammatory disease characterized by optic neuritis (ON) and longitudinally extensive acute transverse myelitis (ATM). First described by Eugene Devic and others in the 19th century as a distinct disease, NMO or Devic’s disease was then classified as a subtype of multiple sclerosis (MS) [1]. However, the discovery of an autoantibody called NMO-IgG that targets aquaporin-4 (AQP4), indicates that NMO is clearly a different CNS pathology [2]. Patients with NMO have an extensive loss of AQP4 and a decreased astrocyte concentration in acute and chronic NMO lesions of the spinal cord and the optic nerves [3].

Brain involvement in NMO patients seems to be more frequent than previously described. Brain MRI at the beginning of the disease is usually normal. However, after a disease course of several years, non-MS-like lesions were found in 50% of patients, whereas MS-like lesions were present in only 10% of cases [4]. Logically, brain lesions in NMO are localized at sites of high AQP4 expression [5]. Using diffusion tensor imaging, brain tissue abnormalities have been found in normal appearing grey matter (NAGM) and normal appearing white matter (NAWM) [6]. Furthermore, using magnetization transfer (MT) MRI, Rocca et al., showed reduced MT ratio of the NAGM [7]. However, magnetic resonance (MR) spectroscopy showed no abnormality in brain NMO, including grey matter (GM) and white matter (WM) [8,9,10].

Only a few NMO patients have undergone brain pathology analysis [4,11,12]. In these cases, macrophage and eosinophil infiltration was found in brain lesions, as previously described in spinal cord lesions [11]. But no pathological data has been published on NAWM and NAGM of brain NMO patients.

We recently demonstrated that NMO patients have cognitive dysfunctions, a finding subsequently confirmed by others [13,14]. The main cognitive deficits were found in long-term memory, speed of information processing, attention and executive functions. As far as we are aware, there have been no previous studies on brain atrophy and cognitive functions in NMO patients.
In the present study, we aimed to investigate whether there are correlations between cognitive dysfunctions and global and/or focal GM and WM volume/concentration in NMO patients.

Materials and Methods

Ethics Statement
All NMO patients and healthy subjects gave their written informed consent to participate in the study. The study was approved by the University Hospital of Strasbourg ethics committee.

Setting and Participants
Twenty-eight patients with definite NMO according to the recently revised criteria [15], and 28 healthy volunteers (control group) matched for sex, age and educational level were included in the study. Patients’ and controls’ characteristics are detailed in Table 1. Patients were recruited at the Department of Neurology (University Hospital of Strasbourg). Twenty-eight patients fulfilled the revised criteria for NMO [15]. All patients had a Beck Depression Inventory score <10 [16], and an EDSS score ≤6.5 [17]. Testing for NMO-IgG was conducted using indirect immunofluorescence analysis, as previously described [18]. Eight patients, including three with cognitive impairment, had also participated in the previously published multicentre study on cognitive functions in NMO [15].

Neuropsychological Assessment
We assessed NMO patients using the the BC cogSEP (Batterie Courte d’évaluation cognitive destine à aux patients souffrant de Scle`rose En Plaques) [13,19]. The BC cogSEP is a battery of tests to evaluate cognitive functions and was specially designed for MS patients. It is the French modified version of the Brief Repeatable Battery of Neuropsychological tests for Multiple Sclerosis (BRB-N) proposed by Rao and comprises the 5 modified BRB-N tests: a Selective Reminding Test (BC cog-SRT), a visuospatial memory test (10/36), the Paced Auditory Serial Addition Test (PASAT), a verbal fluency test, the digit symbol substitution test of the WAIS-R digit span subtest. Cognitive impairment was considered if four or more of the 14 subtests were inferior to the 5th percentile, as described by Dujardin [19]. For the four blind patients we did not perform the 10/36 and the DSST.

Structural Image Analysis
MRI examination of participants was performed on a 1.5 Tesla whole body unit, using a standard head coil (SIEMENS Avanto MR, Erlangen, Germany). Brain MRI was performed the same day as the neuropsychological assessment.

The following sequences were acquired:
(1) 3D high resolution T1-weighted (MPRAGE) images (TR = 1900, TE = 2.68, TI = 1100; flip 15°; FOV 230 mm; matrix 260×320; slice thickness 1.0 mm; voxel size: 1×1×1 mm);
(2) Axial turbo spin-echo (TSE) T2-weighted sequence (TR = 4000, TE = 14/109, echo train length = 5, FOV 220×165 mm², matrix 256×192, slice thickness 4.0 mm);
(3) Axial FLAIR T2-weighted sequence (TR = 9000, TE = 87, TI = 2500, echo train length = 16, FOV 230 mm, matrix 224×256, slice thickness 4.0 mm).

Global brain volume was estimated for each subject with high-resolution T1-weighted images according to the SIENAx method

Table 1. Clinical and demographic features of patients with neuromyelitis optica and controls.

|                         | Patients, n = 28 | Controls, n = 28 | P Value |
|-------------------------|------------------|------------------|---------|
| Age a                   | 45.3 (11.7)      | 42 (15.6)        | >.05    |
| Years of education a    | 12.2 (2.9)       | 12.9 (3.4)       | >.05    |
| Female/male             | 19/9             | 19/9             | >.05    |
| EDSS score b            | 3.42 (0–6.5)     | NA               | NA      |
| Disease duration (years) a | 11.9 (10.9)     | NA               | NA      |
| Immunosuppressant treatment c | 15            | NA               | NA      |
| Immunomodulatory treatment c | 2              | NA               | NA      |
| First signs             | Optic neuritis (n = 17), myelitis (n = 8), optic neuritis and myelitis (n = 2), brainstem signs (n = 1) | NA | NA |
| NMO-IgG+ (%)            | 12 (43)          | NA               | NA      |
| CSF                     | Protein (g/l)    | 0.51             | NA      |
| White cells/mm3a        | 27.0 (45.2)      | NA               | NA      |
| Positive IgG (%) OCB    | 18               | NA               | NA      |

*Mean (standard deviation); 
†Median (range); EDSS = Expanded Disability Status Scale; 
‡At the time of cognitive tests and brain MRI. OCB = oligoclonal bands 
NA = not applicable. 
doi:10.1371/journal.pone.0033878.t001
Briefly, SIENAx estimates the total brain tissue volume, from a single whole-head input image, normalized for skull size. It first strips non-brain tissue, and then uses the brain and skull images to estimate the scaling between the subject’s image and standard space. It then runs tissue segmentation with partial volume estimation to estimate the volume of brain tissue (GM, WM), and applies a normalization factor to reduce head-size-related variability between subjects.

Focal brain volume loss was also analyzed and compared for patients and controls with high-resolution T1-weighted images according to the method for VBM with SPM5 (Statistical Parametric Mapping, Wellcome Department of Cognitive Neurology, London, UK) and Matlab 7.7 software (The MathWorks, MA, USA).

Briefly, this method involves an initial segmentation of T1-weighted MRI into GM and WM images in native space, followed by a normalization of the GM and WM images to GM and WM templates in stereotactic space. To improve segmentation, the normalization parameters obtained from the nonlinear normalization of the GM and WM images are re-applied to the original whole-brain MRI and the normalized whole-brain MRI is then segmented into WM and GM images in a second segmentation step. GM and WM concentration images (i.e., not modulated by the Jacobian of the transformation) were then smoothed with a 12-mm full-width half-maximum (FWHM) Gaussian kernel.

We performed voxel-level correlations of GM or WM concentration between patients and controls, and also between NMO patients with and without cognitive impairment, using a two-sample t-test, without covariates. Statistical maps were thresholded with false discovery rate (FDR) correction with \( P < 0.05 \) and with a minimum cluster size of 30 voxels. MRI Space Utility (MSU, http://www.ibh.spb.ru/pet_lab/MSU/MSUMain.html), xjView software (http://www.alivelearn.net/xjview8/) and Talairach software (http://www.talairach.org/index.html) were used to create reports about cluster localization in terms of Talairach Daemon anatomical region labels.

### Data Analysis

We considered patients to have abnormal cognitive performance if their results were inferior to the 5th percentile, using the norms of Dujardin [19]. We used the residual scores of the BCCogSEP (the difference between the expected and obtained scores) for the cognitive data analysis. The expected score is known because of normative data of the BCCogSEP corrected for age, sex, and educational level [19].

We looked for correlation between cognitive dysfunction and the following parameters: disease duration, EDSS, treatments, NMO antibodies, and also global brain volume, grey matter volume, and white matter volume (normalized). For this statistical analysis, we used the Pearson test for continuous variables, and the Spearman rank correlation test for ordinal data, using SPSS 18. To correct for multiple comparisons, a \( P \) value \( \leq 0.01 \) was considered statistically significant, a \( P \) value between 0.01 and 0.05 was considered as a trend, and a \( P \) value \( > 0.05 \) was considered not significant.

The nonparametric Mann-Whitney U test was used to compare total brain, GM, and WM volumes between patients and controls (SPSS 18).

We performed voxel-level correlations between brain concentration and cognitive performance for each subtest of the BCCogSEP using residual scores with SPM5. An explicit mask was used to ensure that only brain region with decrease concentration of matter were included in the analysis. Statistical maps were thresholded without correction with \( P \) value \(< 0.001\) and with a minimum cluster size of 30 voxels.

### Results

The main demographical, clinical and laboratory results are summarized in Table 1. NMO was monophasic in three cases and multiphasic in the other cases. Four patients were blind. Only three patients had inflammatory lesions of the brain but not fulfilling the Barkhof’s criteria. Two of these three patients had also cognitive impairment.

#### Cognitive Impairment

Fifteen NMO patients (54\%) had cognitive impairment with more than four subtests of the BCCogSEP inferior to the 5th percentile. The results of the cognitive tests are summarized in Table 2. More than 30\% of NMO patients had an impairment in the following tests: the PASAT 3 seconds (3s), the DSST, the BCCog-SRT and the digit span. Among the 6 patients with 10/36 immediate recalls impairment, only two patients had a mild visual acuity impairment. The comparison of NMO patients with cognitive impairment to NMO patients without cognitive impairment showed no differences in terms of age, sex.

Correlations were found between BCCog-SRT learning \( (P = 0.002, \rho = –0.56) \) and EDSS score. A trend towards a correlation was found between PASAT 2s \( (P = 0.03, \rho = –0.42) \) PASAT 3s \( (P = 0.03, \rho = –0.42) \), and EDSS.

No correlation was found between duration of disease, treatment, NMO-IgG antibodies and, and cognitive subtests and number of subtests of BCCogSEP inferior to the 5\( ^{th} \) percentile.

The comparison of characteristics of NMO patients with cognitive impairment \( (N = 13) \) to NMO patients without cognitive impairment \( (N = 13) \) showed no difference in terms of age \( (P = 0.26), sex \( (P = 0.36), \) educational level \( (P = 0.91), \) EDSS \( (P = 0.12) \) and duration of the disease \( (P = 0.14). \)

### Global and Focal Brain Volume

#### Global brain volume.

Using SIENAx, global brain volume of NMO patients was reduced compared to controls \( (P = 0.006; \) Mann-Whitney U). WM brain volume of NMO patients was also reduced compared to controls \( (P = 0.005; \) Mann-Whitney U). No difference in GM brain volume was found between NMO patients and controls \( (P = 0.81; \) Mann-Whitney U). Mean whole brain volume of NMO patients was 1582244.1 mm\(^3\)±29733.8 and mean whole brain volume of controls was 1643541.6 mm\(^3\)±6829.5. Mean WM brain volume of NMO patients was 762744.1 mm\(^3\) and mean WM brain volume of controls was 816182.4 mm\(^3\)±66658.9. Mean GM brain volume of NMO patients was 819500.1 mm\(^3\)±79067.8, and mean GM brain volume of controls was 829139.2 mm\(^3\)±87229.7.

Correlation was found between the number of subtests inferior to 5\( ^{th} \) percentile and normalized global brain volume \( (P = 0.007, \rho = –0.50) \). A trend towards a correlation was found between the number of subtests inferior to the 5\( ^{th} \) percentile to the BCCogSEP and normalized WM volume \( (P = 0.02, \rho = –0.43) \).

A trend towards a correlation was found between normalized WM volume and PASAT 3s \( (P = 0.024, \rho = 0.40) \) and PASAT 2s \( (P = 0.046, \rho = 0.36) \).

Using SIENAx, global brain volume of NMO patients with cognitive impairment \( (N = 13) \) was reduced compared to global brain volume of NMO patients without cognitive impairments \( (N = 13) \) \( (P = 0.006; \) Mann-Whitney U). WM brain volume of NMO patients with cognitive impairment was also reduced compared to WM volume of NMO patients without cognitive
impairment ($P=0.005$; Mann-Whitney U). No difference was found between GM brain volume of NMO with and without cognitive impairment ($P=0.22$; Mann-Whitney U).

Focal brain volume. Using VBM, focal brain atrophy of the WM was found as shown in Fig. 1 and Table 3. No focal brain atrophy of the GM was found.

Correlations between focal brain volume and cognitive tests. Because we did not find any decreased volume in GM of NMO patients, we did not look for correlations between GM volume and cognitive tests.

No correlation was found between few cognitive subtests (crossed tapping test, Go/No-Go test, and semantic fluency) and regional white matter volume in the NMO group.

Correlations were found between regional white matter volume and the PASAT 3s, DSST, phonemic fluency, forward and backward digit span, BCcog-SRT and 10/36 spatial memory test, as shown in Table 4.

BCcog-SRT was correlated to the fornix, and the WM of middle frontal gyrus, hippocampus and lingual gyrus. Backward digit span was correlated to WM of the left medial frontal gyrus, and forward digit span to the left middle temporal gyrus. Phonemic fluency was correlated to the WM of thalamus.

DSST was correlated to the WM of the middle frontal gyrus and precentral gyrus. PASAT 3s was correlated to the WM of corpus callosum, frontal and parietal regions and the pons (Fig. 2).

Two main structures were correlated with 10/36 immediate recall: parietal lobe and limbic lobe, including parahippocampal structures. Many white matter structures were correlated with 10/36 delayed recall: parts of the visual system (optic chiasm and occipital lobe), parts of the frontal lobe, part of the limbic system

---

**Table 2.** Number (percentage) of NMO patients with a score inferior to the 5th percentile for each cognitive subtests of the BCcogSEP.

| Cognitive Tests                        | Number of patients with cognitive dysfunction (percentage) |
|----------------------------------------|----------------------------------------------------------|
| Selective reminding test (SRT)         |                                                           |
| Mean number of words                   | 11 (39.3)                                                |
| Learning                               | 12 (42.9)                                                |
| SRT-DR (delayed recall)                | 9 (32.1)                                                 |
| 10/36 Spatial Recall Test*             |                                                           |
| Immediate recall                       | 6 (25.0)                                                 |
| Delayed recall                         | 3 (12.5)                                                 |
| Digit Span                             |                                                           |
| Forward                                | 7 (25.0)                                                 |
| Backward                               | 9 (32.1)                                                 |
| Digit symbol substitution test (DSST)* | 11 (45.8)                                                |
| Paced Auditory Serial Addition Test (PASAT) |                                                |
| 2 s                                    | 7 (25.0)                                                 |
| 3 s                                    | 11 (39.3)                                                |
| Crossed tapping                        | 3 (10.7)                                                 |
| Go/no-go                               | 4 (14.3)                                                 |
| Fluencies                              |                                                           |
| Phonemic                               | 8 (28.6)                                                 |
| Semantic                               | 4 (14.3)                                                 |
| BCcogSEP battery                       | 15 (54)                                                  |

**Note:** Blind patients were not tested for these tests.

NMO = Neuromyelitis Optica; BCcogSEP = French translation of the Brief Repeatable Battery.

doi:10.1371/journal.pone.0033878.t002

---

Figure 1. White matter volume regional differences between the NMO group (n=28) and the control group (n=28) using VBM. Note that the NMO group overall showed a decreased WM volume in the frontal and parietal lobes (including the superior longitudinal fascicle), corpus callosum, cerebellum, brainstem and optic chiasm compared to healthy control subjects. ($P<0.05$, false discovery rate, cluster size threshold >30 voxels).

doi:10.1371/journal.pone.0033878.g001
including parahippocampal regions, part of the parietal lobe including post-central gyrus and inferior parietal lobule, and the vermis.

**Comparison of focal brain volume between NMO patients with and without cognitive impairment.** We did not find any focal GM volume difference between NMO patients with cognitive impairment (n = 15) and without cognitive impairment. On the contrary, a large decrease of the WM when we compared NMO patients with cognitive impairment to NM patients without cognitive impairment was found (Fig. 3). These differences included brainstem, cerebellum, corticospinal tracts but also important fascicles of the brain such as corpus callosum, superior longitudinal fascicle and inferior longitudinal fascicle.

**Discussion**

Our data show that 54% of NMO patients had cognitive impairment according to their BCogSEP performances. We also found a decreased global and focal white matter volume in NMO patients compared to healthy subjects. Furthermore, we observed that the majority of the WM is decreased in NMO patients with cognitive impairment compared to NM patients without cognitive impairment. We observed also correlations between cognitive tests performance and white matter volume; We did not find any global and focal GM differences between NMO patients and controls, and also between NMO patients with and without cognitive impairment.

We demonstrated cognitive impairment in more than half of NMO patients in a previously published multicentre study [13]. Recently, Saji et al. and He et al. also reported cognitive impairment in NMO patients [14,23]. In these three studies and the present study, the cognitive pattern in NMO patients was a “subcortical” cognitive impairment, including a decreased speed treatment of information (DSST, PASAT), executive function impairment (PASAT, fluencies), attention impairment (PASAT, forward and backward digit span) and memory impairment (BCog-SRT, 10/36). The term “subcortical” was first used by K. Wilson when he described in 1912 patients with Wilson’s disease with cognitive deficits different from other dementias, and then for patients with degenerative extrapyramidal disorders (Cummings, 1986). This term is also used for inflammatory diseases. This term “subcortical” is particularly coherent with NMO patients where the cognitive pattern and the atrophy pattern seem to be linked to the WM involvement.

In the previous two studies, there was no correlation between brain lesions and cognitive impairment[13,14]. In the present study, only three patients had brain inflammatory lesions, and among them two patients had cognitive impairment.

We wanted also to better understand the relationship between white and grey matter volumes and cognitive functions in NMO patients. We did not find any decrease of brain GM volume in NMO patients, using SIENAs for global volume and VBM in SPM5 for focal volume. Moreover, the comparison of global and focal GM of NMO patients with and without cognitive impairment did not show any decreased volume. Similarly using MR spectroscopy of the brain we did not find any abnormality in the GM in an earlier study [8], and pathological analysis of brain NMO patients did not reveal cortical demyelination [24]. However, it seems that brain NAGM in NMO has a decreased MT ratio [7]. Furthermore, abnormal diffusivity (increased mean diffusivity) of NAGM has been reported [6]. These abnormalities

| Region | BA vicinity | Side | No. of voxels | T | Coordinates (mm) | P |
|--------|-------------|------|---------------|---|-----------------|---|
|        |             |      |               |   | x               | y | z |
| Frontal lobe and parietal lobes, superior frontal gyrus, precentral gyrus, postcentral gyrus and frontal superior medial | 1, 2, 3, 6, 8 and 9 | Bilateral | 14750 | 5.47 | -12 6 70 | 0.009 |
| Frontal lobe, superior and medial frontal gyrus, frontal superior orbital | 11 | R | 458 | 4.98 | 6 66 -26 | 0.010 |
| Optic chiasm | NA | Bilateral | 994 | 4.71 | 8 6 -22 | 0.010 |
| Cerebellum, posterior lobe | NA | R | 188 | 4.29 | 60 -46 -34 | 0.019 |
| Frontal lobe, sub-gyral, anterior corpus callosum and superior longitudinal fascicle | NA | R | 927 | 4.17 | 22 28 20 | 0.013 |
| Cerebellum, anterior lobe, culmen of vermis | NA | L | 433 | 4.03 | -2 -66 -10 | 0.017 |
| Temporal lobe, superior and middle temporal gyrus | 22 | L | 206 | 3.99 | -42 -28 -6 | 0.015 |
| Cerebellum, posterior lobe and brainstem, pons and middle cerebellar peduncle | NA | L | 663 | 3.83 | -16 -30 -54 | 0.018 |
| Frontal lobe, middle frontal gyrus | 8 | L | 76 | 3.77 | -40 28 46 | 0.019 |
| Cerebellum, posterior lobe | NA | R | 53 | 3.70 | 54 -54 -56 | 0.020 |
| Posterior corpus callosum | NA | Bilateral | 848 | 3.50 | 2 -26 14 | 0.023 |
| Limbic lobe, hippocampus and optic tract | NA | L | 104 | 3.47 | -24 -22 -8 | 0.023 |
| Temporal lobe, superior temporal gyrus and insula | 38, 21 | R | 80 | 3.44 | 50 6 -10 | 0.023 |
| Cerebellum, anterior lobe, culmen | NA | Bilateral | 206 | 3.33 | -54 -44 -26 | 0.026 |
| Parietal lobe, postcentral gyrus | 40 | L | 39 | 3.28 | -72 -22 16 | 0.028 |
| Brainstem, pons | NA | R | 243 | 3.21 | 12 -16 38 | 0.030 |

For each cluster, the extension in which local maxima are located, along with the coordinates in the MNI space and the T level of the most significant voxel are reported. T = P<0.05, corrected using false discovery rate (FDR). BA = Brodmann’s area, L = left, R = right, NA = not applicable.

doi:10.1371/journal.pone.0033878.t003
Table 4. Correlation between performance on cognitive tests and regional white matter volume.

| Cognitive subtests         | Regions of white matter                                                                                     | BA vicinity | Side | No. of voxels | T value | x    | y    | z     | P      |
|----------------------------|-------------------------------------------------------------------------------------------------------------|-------------|------|---------------|---------|------|------|-------|--------|
| 10/36 imm. recall          | Parietal lobe, inferior parietal lobule, supramarginal gyrus                                               | 40, 2       | R    | 265          | 5.61    | 54   | –30  | 28    | 0.000  |
|                            | Parietal lobe, postcentral gyrus, inferior parietal lobule                                                 | 40, 3, 2    | L    | 140          | 5.20    | –34  | –38  | 58    | 0.000  |
|                            | Parietal lobe, inferior parietal lobule, subgyral                                                          | 13          | L    | 222          | 5.08    | –40  | –40  | 24    | 0.000  |
|                            | Limbic lobe, parahippocampal gyrus, hippocampus, uncus                                                     | NA          | R    | 2475         | 5.02    | 24   | –8   | –26   | 0.000  |
|                            | Frontal lobe, middle frontal gyrus, precentral gyrus                                                      | 6           | L    | 132          | 5.02    | –44  | 2    | 44    | 0.000  |
|                            | Cerebellum, anterior lobe, vermis                                                                          | NA          | R/L  | 458          | 4.62    | 8    | –52  | –34   | 0.000  |
|                            | Limbic lobe, parahippocampal gyrus                                                                        | NA          | L    | 133          | 4.49    | –26  | –10  | –28   | 0.000  |
| 10/36 delayed recall       | Frontal lobe, middle frontal gyrus, precentral gyrus                                                      | 6           | L    | 270          | 6.82    | –46  | 4    | 48    | 0.000  |
|                            | Parietal lobe, inferior parietal lobule and Limbic lobe, parahippocampal gyrus, including the superior longitudinal fascicle, the corpus callosum and the chiasm | 40          | R/L  | 8537         | 6.39    | 50   | –32  | 26    | 0.000  |
|                            | Cerebellum, anterior lobe, nodule, vermis                                                                  | NA          | R    | 1391         | 5.89    | 8    | –58  | –34   | 0.000  |
|                            | Frontal lobe, middle frontal gyrus                                                                        | 46          | R    | 175          | 5.83    | 32   | 34   | 16    | 0.000  |
|                            | Frontal lobe, medial frontal gyrus                                                                        | 32, 10      | L    | 158          | 5.49    | –18  | 48   | –4    | 0.000  |
|                            | Parietal lobe, postcentral gyrus                                                                           | 3, 40       | L    | 576          | 5.47    | –34  | –38  | 58    | 0.000  |
|                            | Occipital lobe, subgyral, inferior occipital gyrus                                                         | 18          | L    | 410          | 5.39    | –32  | 106  | –12   | 0.000  |
|                            | Frontal lobe, superior frontal gyrus, supplementary motor area                                             | 6           | R    | 141          | 5.31    | 14   | 16   | 60    | 0.000  |
|                            | Frontal lobe, middle frontal gyrus, middle fronto-orbital gyrus                                            | 10, 11      | R    | 217          | 5.21    | 48   | 52   | –8    | 0.000  |
|                            | Occipital lobe, cuneus                                                                                      | 17          | R    | 260          | 5.11    | 22   | –100 | –6    | 0.000  |
|                            | Occipital lobe, middle occipital gyrus                                                                      | 19, 18      | L    | 193          | 5.06    | –54  | –86  | –6    | 0.000  |
|                            | Frontal lobe, middle frontal gyrus, precentral gyrus                                                      | 6           | R    | 503          | 4.99    | 44   | 6    | 54    | 0.000  |
|                            | Temporal lobe, middle temporal gyrus                                                                       | 20, 37, 21  | L    | 127          | 4.79    | –58  | –40  | –18   | 0.000  |
|                            | Frontal lobe, middle frontal gyrus                                                                          | 46          | L    | 200          | 4.78    | –54  | 38   | 32    | 0.000  |
|                            | Parietal lobe, inferior parietal lobule                                                                     | 40, 2       | L    | 190          | 4.42    | –54  | –36  | 34    | 0.000  |
|                            | Phonemic fluency                                                                                             | Thalamus     | NA   | 430          | 5.79    | 8    | –20  | 10    | 0.000  |
|                            | Forward digit span                                                                                            | Temporal lobe, middle temporal gyrus                                                                     | 21, 20, 37 | L    | 155          | 5.10    | –62  | –42  | –12   | 0.000  |
|                            | Backward digit span                                                                                           | Frontal lobe, medial frontal gyrus                                                                       | 25          | L    | 33           | 4.14    | 50   | 8    | 62    | 0.000  |
|                            | DSST                                                                                                         | Frontal lobe, middle frontal gyrus, precentral gyrus                                                     | 6, 4        | R    | 173          | 5.00    | 52   | 8    | 54    | 0.000  |
|                            | PASAT 3s                                                                                                      | Brainstem, pons                                                                                           | NA          | R    | 103          | 4.68    | 12   | –18  | –42   | 0.000  |
|                            | Frontal and parietal lobes, precentral gyrus, postcentral gyrus                                            | 1, 6, 4, 3   | L    | 252          | 4.48    | –54  | –26  | 64    | 0.000  |
|                            | Frontal lobe, precentral gyrus                                                                               | 6           | R    | 54           | 4.41    | 56   | –2   | 60    | 0.000  |
|                            | Corpus callosum                                                                                               | NA          | R    | 63           | 4.23    | 4    | 22   | 10    | 0.000  |
|                            | Frontal lobe, supplementary motor area                                                                       | 6           | L    | 79           | 4.20    | –16  | –6   | 62    | 0.000  |
|                            | Frontal lobe, paracentral lobule                                                                             | 3, 6, 4     | R    | 96           | 4.03    | 12   | –34  | 64    | 0.000  |
|                            | Frontal lobe, inter-hemispheric, subcallosal gyrus                                                           | 25          | R/L  | 209          | 4.32    | 6    | 6    | –20   | 0.000  |
|                            | Corpus callosum                                                                                               | NA          | R/L  | 251          | 3.97    | 10   | –8   | 18    | 0.000  |
|                            | Frontal lobe, superior frontal gyrus, supplementary motor area                                              | 6           | R    | 98           | 3.96    | 18   | 12   | 64    | 0.000  |
|                            | SRT, mean number of words                                                                                   | Frontal lobe, middle frontal gyrus                                                                         | 6           | R    | 36           | 3.95    | 8    | –12  | 16    | 0.000  |
|                            | Fornix, thalamus                                                                                              | NA          | R    | 43           | 3.61    | 8    | –14  | 18    | 0.000  |
|                            | SRT, delayed recall                                                                                            | Temporal lobe, subgyral, hippocampus                                                                      | NA          | L    | 35           | 4.06    | –20  | –84  | 0    | 0.000  |
|                            | Occipital lobe, lingual gyrus                                                                                | 17          | L    | 34           | 3.80    | –38  | –30  | –6    | 0.000  |
|                            | Fornix, thalamus                                                                                              | NA          | R/L  | 95           | 3.59    | 8    | –12  | 16    | 0.000  |
of grey tissues have mainly been found in regions connected with the spinal white matter tracts and optic nerves [6].

We found a decrease in WM brain volume in NMO patients, using SIENAx for global volume and VBM in SPM5 for focal volume. This result, found using two different methods, strengthens the discovery of such atrophy. Abnormalities of NAWM in the brain of NMO patients were previously found using diffusion tensor imaging [6,7]. Yu et al. found a higher average mean diffusivity (MD) and a lower average fraction of anisotropy (FA). MD measures the average molecular motion and is affected by integrity, and FA reflects the degree of alignment of cellular structures and their structural integrity [25]. Thus, subtle lesions of the WM could be responsible for abnormal diffusion and atrophy. Using VBM, we found a decrease in the WM concentration in particular regions. First, we found atrophy in the optic chiasm and optic tracts, which are regions known to be involved in NMO. We also found atrophy in regions connected to the cortico-spinal tract, such as the WM in the brainstem and the precentral and postcentral gyri. These data are coherent with the known involvement of the spinal cord and the optic nerves in NMO. One can suppose that retrograde degeneration is potentially responsible for this atrophy of white matter. Yet, we also found atrophy of other regions not involved in the optic or corticospinal tracts. Thus, we found WM atrophy of the cerebellum: this data is coherent with previous studies that have found cerebellum lesions in NMO [4,26]. Neuropathologically, Popescu et al., did not find any demyelination of the GM of the cerebellum, and more pathological data are needed on the brain WM, even if case of cerebellum involvement has been described [24,27]. WM atrophy of many parts of frontal, parietal (including superior longitudinal fascicle), temporal and corpus callosum regions has been found (Figure 1 and Table 3). These data would appear to conflict with the results we previously published concerning the analysis of the brain of NMO patients with MR spectroscopy, in which no abnormality was found in the WM. However, in that study we focused the analysis on the centrum ovale [8]. To our best knowledge, no study has tested the whole brain using MR spectroscopy in NMO.

We also observed correlations between cognitive test performances and WM volumes. First, we found an association between low performance for immediate and delayed spatial memory (10/36 immediate and delayed recall) and a reduced volume of the optic chiasm, the corpus callosum, limbic lobe including parahippocampal gyrus and fronto-parieto-occipital regions including the superior longitudinal fascicle. Visual impairment could explain difficulties in performing a visual memory task. Thus, the correlation found with the optic chiasm is logical. Chronic disconnection of the corpus callosum by surgery is known to be responsible for moderate memory impairment, particularly topographical memory [28]. Moreover, some cases of stroke in the corpus callosum and posterior thalamus have shown memory impairment [29]. The parahippocampal gyrus are regions well-known to be involved in memory, particularly in spatial memory (where stream) [30]. Finally, the fronto-parietal network, including the superior longitudinal fascicle and the parietal cortex are also of importance for memory, particularly spatial working memory [31,32].

Reduced WM in the pons was correlated with poor performances on PASAT. Norepinephrine-synthesizing neurons that send diffuse projection from a part of the pons, the locus coeruleus, have a major role in attention, particularly in focused attention and the ability to redirect attention [33,34]. Attention is of high importance to succeed in performing the PASAT. PASAT 3s was also correlated with the corpus callosum. Anterior callosal abnormalities are reported to be correlated with impaired PASAT performance in MS [35]. In the same way, impaired PASAT was associated with numerous little frontal WM regions involved in the working memory [36]. Bcog-SRT, a verbal memory test, was found to be correlated logically to regions of importance for episodic memory (thalamus, fornix, hippocampus, frontal lobe) and for recognizing words (lingual gyrus) [37]. Digit span was found to be correlated with perisylvian atrophy, as previously described [38]. DSST, a speed writing test, was found to be correlated with the precentral gyrus, which is also the primary motor cortex, indispensible to do this test.

He et al., have recently demonstrated significantly correlations between corpus callosum, frontal regions and cognitive tests concerning verbal memory and speed of information processing [23]. Thus, with PASAT, they found correlations with corpus callosum (fraction of anisotropy and mean diffusivity). These data are coherent with ours showing also the involvement of the corpus callosum.

Table 4. Cont.

| BA | DSST | imm. | L | R | NA | PASAT |
|----|------|------|---|---|----|-------|
| 10.1371/journal.pone.0033878.t004

Figure 2. Correlation between performance on PASAT 3 seconds and regional white matter volumes of 28 NMO patients, using VBM. Note the correlations with corpus callosum and the pons. Statistical maps were thresholded without correction, with a value <0.001 and with a minimum cluster size of 30 voxels.

doi:10.1371/journal.pone.0033878.g002
The diminished WM volume of NMO patients with cognitive impairment compared to NMO without cognitive impairment is highly diffuse (Figure 3). The majority of the brain WM is involved using the VBM method. Moreover, the same result is found using the SIENAx method with a high significance. Because there was no difference in terms of age, sex, educational level, NMO-IgG antibodies and EDSS, these quite clear results raise to the question: is there two types of NMO patients: those with cognitive impairment and perhaps brain involvement and those without the twos. The figure 3 illustrating this result confirms also the involvement of cerebellum, brainstem, corpus callosum, superior longitudinal fascicle and many WM regions of the brain including frontal, parietal, temporal and occipital regions, in the cognitive impairment of NMO patients.

WM atrophy detected with two methods and correlations between WM and cognitive tests, are important arguments in favour of brain WM involvement in NMO. NMO is an inflammatory disease of the CNS. AQP4 is known to be the main target antigen involved in this disease. AQP4 is a bidirectional water channel, found on all surfaces of astrocytes. The highest concentration of AQP4 is in the perivascular and peripial end-feet, in direct contact with the endothelium and pia mater, respectively. AQP4 immunoreactivity of the WM in the brain is highest and mesh-like in the chiasm, the optic nerves and the brainstem, particularly in the pons (at the floor of the fourth ventricle) [39]. These regions were found to be atrophic in NMO patients in comparison with controls. The other areas of white matter found to be atrophic, including the frontal and parietal lobes and the corpus callosum, have more limited AQP4 concentration on the surface of blood vessels [39]. This discrepancy between atrophy and AQP4 concentration in these area could be explained partly by a secondary degeneration caused by lesions in the spinal cord and optic nerves [40].

There are some limitations to our study. Firstly, our cohort of NMO patients has only 43% of patients with NMO-IgG positivity. In North American patients, particularly in the Mayo Clinic (Rochester, MN, USA), NMO-IgG positivity was reported to be 73% [2]. However, a more recent figure for NMO-IgG positivity ascertained by immunofluorescence in the Mayo clinic is 58% (95% confidence interval: 42–72) [41]. Moreover, we demonstrated that among 111 patients in a French NMO cohort, only 54% had positive NMO-IgG and this test was necessary in order to confirm the diagnosis, using Wingerchuk's criteria, in only 10% of the cohort [15,42]. Secondly, the SIENAx method seems to have some limitations to evaluate brain atrophy. Thus, Sharma et al., recently demonstrated, using an atrophy simulation of the brain, with various sources of error (bias-field inhomogeneity, noise, etc.), that SIENAx has a mean absolute error of evaluation of 3 to 4% (against 0.5% for SIENA) [43]. Nonetheless, we also found white matter atrophy in NMO patients when we used SPM5 software.

Conclusion

Fifty-four percent of the NMO patients in our study had cognitive impairment according to their performance on the French version of the BRB-N. We found also a decreased global and focal white matter volume in the brain of NMO patients compared to healthy subjects. Furthermore, NMO patients with cognitive impairment have an important atrophy of brain WM compared to NMO patients without cognitive impairment. We observed also correlations between cognitive tests performances and WM concentrations. Further studies are now needed to elucidate more precisely the origin of cognitive impairment in the brain of NMO patients, particularly in the WM. We are therefore planning to use diffusion tensor imaging (DTI) to analyse the correlations between cognitive impairment and DTI parameters. More pathological data are also needed to better understand the mechanisms of cognitive impairment in NMO patients.

Author Contributions

Conceived and designed the experiments: FB JdS. Performed the experiments: FB NL N. Cremel LdB CK SK. Analyzed the data: FB VN Bj FR FR JF JPA. Contributed reagents/materials/analysis tools: FB N. Collongues BB JdS. Wrote the paper: FB.
References

1. Gault F (1894) De la Neuromyélite Optique aiguë. Thèse à la faculté de Médecine et de Pharmacie de Lyon 981.

2. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittoc SJ, Lucchinetti CF, et al. (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106–2112.

3. Misu T, Fujihara K, Kakita A, Kono H, Nakamura M, et al. (2007) Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130: 1214–1234.

4. Pittoc SJ, Lennon VA, Krecek K, Wingerchuk DM, Lucchinetti CF, et al. (2006) Brain abnormalities in neuromyelitis optica. Arch Neurol 63: 390–396.

5. Rocca MA, Agosta F, Mezzapesa DM, Martindelli V, Salvi F, et al. (2004) Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica. Neurology 62: 476–478.

6. de Seze J, Blanc F, Kremer S, Collongues N, Fleury M, et al. (2010) Magnetic resonance spectroscopy evaluation in patients with neuromyelitis optica. J Neurol Neurosurg Psychiatry 81: 409–411.

7. Rocca MA, Agosta F, Mezzapesa DM, Martindelli V, Salvi F, et al. (2004) Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica. Neurology 62: 476–478.

8. de Seze J, Blanc F, Kremer S, Collongues N, Fleury M, et al. (2010) Magnetic resonance spectroscopy evaluation in patients with neuromyelitis optica. J Neurol Neurosurg Psychiatry 81: 409–411.

9. Aboul-Enein F, Krssak M, Hoftberger R, Prayer D, Kristoferitsch W (2010) Neuromyelitis optica with clinical and histopathological involvement of the brain. Mult Scler 16: 436–443.

10. Bichuetti DB, Rivero RL, de Oliveira EM, Oliveira DM, de Souza NA, et al. (2008) Lack of cerebral atrophy in patients with neuromyelitis optica. APMIS 116: 296–301.

11. Hengstman GJ, Wesseling P, Frenken CW, Jongen PJ (2007) Neuromyelitis optica-IgG and Devic’s neuromyelitis optica: a French experience. Mult Scler 13: 679–682.

12. Nakamura M, Endo M, Murakami M, Kono H, Fujihara K, et al. (2005) An autopsied case of neuromyelitis optica with a large cavitory cerebral lesion. Mult Scler 11: 735–738.

13. Blanc F, Zephir H, Lebrun C, Labauge P, Castelnovo G, et al. (2008) Cognitive functions in neuromyelitis optica. Arch Neurol 65: 84–88.

14. Saji E, Toyoshima Y, Yanagawa K, Nishizawa M, Kawachi I (2010) Neuropsychiatric Presentation of Neuromyelitis Optica Spectrum Disorders. Neurology 74: A169.

15. Wingerchuk DM, Lennon VA, Pittoc SJ, Lucchinetti CF, Weisheinber BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66: 1485–1489.

16. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4: 561–571.

17. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444–1452.

18. Marignier R, De Seze J, Vukusic S, Durand-Dubief F, Zephir H, et al. (2008) NMO-IgG and Devic’s neuromyelitis optica: a French experience. Arch Neurol 65: 416–420.

19. Yu CS, Lin FC, Li KC, Jiang TZ, Zhu CZ, et al. (2006) Diffusion tensor imaging in the assessment of normal-appearing brain tissue damage in relapsing neuromyelitis optica. AJNR Am J Neuroradiol 27: 1009–1015.

20. Rocca MA, Agosta F, Mezzapesa DM, Martindelli V, Salvi F, et al. (2004) Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica. Neurology 62: 476–478.

21. de Seze J, Blanc F, Kremer S, Collongues N, Fleury M, et al. (2010) Magnetic resonance spectroscopy evaluation in patients with neuromyelitis optica. J Neurol Neurosurg Psychiatry 81: 409–411.

22. Aboul-Enein F, Krssak M, Hoftberger R, Prayer D, Kristoferitsch W (2010) Neuromyelitis optica with clinical and histopathological involvement of the brain. Mult Scler 16: 436–443.

23. He D, Wu Q, Chen X, Zhao D, Gong Q, et al. (2011) Cognitive impairment and whole brain diffusion in patients with neuromyelitis optica after acute relapse. Brain Cogn 78: 80–88.

24. Popescu BF, Parisi JE, Calderon-Gomez JA, Newell K, Mandell RN, et al. (2010) Absence of cortico-medullar demyelination in neuromyelitis optica. Neurology 75: 2103–2109.

25. Basser PJ, Pierp se C (1996) Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B 111: 209–219.

26. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444–1452.

27. Chalumeau-Lemoine L, Chertien F, Gaedle St Larbi A, Brugerier P, Gray F, et al. (2006) Devic disease with brainstem lesions. Arch Neurol 63: 591–593.

28. Zaidel DW (1995) The case for a relationship between human memory, hippocampus and corpus callosum. Biol Res 28: 51–57.

29. Kim JH, Park KY, Seo SW, Na DL, Chung CS, et al. (2007) Reversible verbal and visual memory deficits after left retrotemporal infarction. J Clin Neurol 3: 62–66.

30. Eichenbaum H, Lipton PA (2008) Towards a functional organization of the medial temporal lobe memory system: role of the hippocampal and entorhinal cortical areas. Hippocampus 18: 1314–1324.

31. Vestergaard M, Madsen KS, Baarre WF, Skimminge A, Ejerho LR, et al. (2011) White matter microstructure in superior longitudinal fasciculus associated with spatial working memory performance in children. J Cogn Neurosci 23: 2135–2146.

32. Cabeza R, Casarlemelli E, Olson IR, Moscovich M (2008) The parietal cortex and episodic memory: an attentional account. Nat Rev Neurosci 9: 613–625.

33. Benarroch EE (2009) The locus coeruleus norepinephrine system: functional organization and potential clinical significance. Neurology 73: 1609–1704.

34. Sara SJ (2009) The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci 10: 211–223.

35. Ozturk A, Smith SA, Gordon-Lapkin EM, Harrison DM, Shire N, et al. (2010) MRI of the corpus callosum in multiple sclerosis: association with disability. Mult Scler 16: 166–177.

36. Blełdowski C, Kaiser J, Rahm B (2010) Basic operations in working memory: contributions from functional imaging studies. Behav Brain Res 214: 172–179.

37. Tulving E (2002) Episodic memory: from mind to brain. Annu Rev Psychol 53: 1–25.

38. Korninis M, Acherson DJ, Barkey AK, Soloman J, Posdle BR, et al. (2011) Areas of left periinsular cortex mediate auditory-verbal short-term memory. Neuropsychologia 49: 3612–3619.

39. Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, et al. (2007) Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130: 1194–1205.

40. Yu C, Lin F, Li K, Jiang T, Qin W, et al. (2008) Pathogenesis of normal-appearing white matter damage in neuromyelitis optica: diffusion-tensor MR imaging. Radiology 246: 222–226.

41. McKees A, Fryer JP, Apivatanakul M, Lennon VA, Hinson SR, et al. (2009) Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol 66: 1134–1138.

42. Collongues N, Marignier R, Zephir H, Papeix C, Blanc F, et al. (2010) Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 74: 736–742.

43. Sharma S, Nohlet V, Rousseau F, Heitz F, Rumbach L, et al. (2010) Evaluation of brain atrophy estimation algorithms using simulated ground-truth data. Med Image Anal 14: 373–389.